Sarcoma  >>  Farydak (panobinostat)  >>  Phase 2
Welcome,         Profile    Billing    Logout  

3 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Farydak (panobinostat) / Secura Bio
ESTIM-LBH, NCT01136499 / 2009-011280-37: Efficacy and Safety Assessment of Oral LBH589 in Adult Patients With Advanced Soft TIssue Sarcoma After Pre-treatment Failure

Completed
2
53
Europe
LBH589 (Panobinostat®), panobinostat
Centre Leon Berard
Soft Tissue Sarcoma
01/12
01/13
NORTH, NCT04897880 / ACTRN12618000321246: A Study of Panobinostat in Pediatric Patients With Solid Tumors Including MRT/ATRT

Terminated
2
25
US, RoW
Panobinostat, Farydak®
Australian & New Zealand Children's Haematology/Oncology Group, National Health and Medical Research Council, Australia, Secura Bio, Inc.
Rhabdoid Tumor, Atypical Teratoid/Rhabdoid Tumor, Malignant Rhabdoid Tumor, Recurrent Brain Tumor, Childhood
12/21
12/21
ACTRN12618000321246: A Phase II Study of Panobinostat in Paediatric, Adolescent and Young Adult Patients with Solid Tumours Including Osteosarcoma, Malignant Rhabdoid Tumour/Atypical Teratoid Rhabdoid Tumours and Neuroblastoma.

Active, not recruiting
2
60
 
Australian and New Zealand Children’s Haematology and Oncology Group (ANZCHOG), NHMRC
Osteosarcoma, Malignant Rhabdoid Tumour, Neuroblastoma, Atypical Teratoid/Rhabdoid Tumour (AT/RT)
 
 

Download Options